Vertex Pharmaceuticals Reports Phase 3 Results for Suzetrigine in Acute Pain

Vertex Pharmaceuticals today announced Phase 3 trial results for suzetrigine in patients with moderate-to-severe acute pain following surgery. The trials demonstrated significant reductions in pain scores compared to placebo, with suzetrigine showing a favorable safety profile without the opioid-associated side effects of respiratory depression, sedation, or addiction potential. These results led to FDA approval of suzetrigine as the first non-opioid analgesic with a new mechanism of action in over 20 years.